4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2025)
Historic Change in Account Payables for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$1.8 million.
- 4D Molecular Therapeutics' Change in Account Payables fell 26161.42% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 33460.39%. This contributed to the annual value of $871000.0 for FY2024, which is 279.02% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Change in Account Payables of -$1.8 million as of Q3 2025, which was down 26161.42% from $4.5 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Change in Account Payables' 5-year high stood at $4.5 million during Q2 2025, with a 5-year trough of -$1.8 million in Q3 2025.
- Its 5-year average for Change in Account Payables is $257421.1, with a median of $226000.0 in 2022.
- Per our database at Business Quant, 4D Molecular Therapeutics' Change in Account Payables crashed by 31345.91% in 2022 and then soared by 67875.32% in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Change in Account Payables (Quarter) stood at $1.7 million in 2021, then fell by 8.97% to $1.5 million in 2022, then crashed by 171.91% to -$1.1 million in 2023, then skyrocketed by 234.38% to $1.5 million in 2024, then tumbled by 225.65% to -$1.8 million in 2025.
- Its Change in Account Payables stands at -$1.8 million for Q3 2025, versus $4.5 million for Q2 2025 and -$235000.0 for Q1 2025.